PT3712147T - Inibidor de sglts e sua aplicação - Google Patents

Inibidor de sglts e sua aplicação

Info

Publication number
PT3712147T
PT3712147T PT197357122T PT19735712T PT3712147T PT 3712147 T PT3712147 T PT 3712147T PT 197357122 T PT197357122 T PT 197357122T PT 19735712 T PT19735712 T PT 19735712T PT 3712147 T PT3712147 T PT 3712147T
Authority
PT
Portugal
Prior art keywords
application
sglts inhibitor
sglts
inhibitor
Prior art date
Application number
PT197357122T
Other languages
English (en)
Original Assignee
Shandong Danhong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Danhong Pharmaceutical Co Ltd filed Critical Shandong Danhong Pharmaceutical Co Ltd
Publication of PT3712147T publication Critical patent/PT3712147T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/14Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/20Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hydrogen atoms and substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D309/22Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
PT197357122T 2018-01-05 2019-01-04 Inibidor de sglts e sua aplicação PT3712147T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810012284 2018-01-05

Publications (1)

Publication Number Publication Date
PT3712147T true PT3712147T (pt) 2023-03-21

Family

ID=67144362

Family Applications (1)

Application Number Title Priority Date Filing Date
PT197357122T PT3712147T (pt) 2018-01-05 2019-01-04 Inibidor de sglts e sua aplicação

Country Status (10)

Country Link
US (1) US10822365B1 (pt)
EP (1) EP3712147B8 (pt)
JP (1) JP6917527B2 (pt)
KR (1) KR102283677B1 (pt)
CN (1) CN111372930B (pt)
AU (1) AU2019205072B2 (pt)
ES (1) ES2941108T3 (pt)
FI (1) FI3712147T3 (pt)
PT (1) PT3712147T (pt)
WO (1) WO2019134667A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220153772A1 (en) * 2019-03-29 2022-05-19 Medshine Discovery Inc. Glucoside derivative that acts as sglt1 inhibitor and application thereof
KR20220030930A (ko) * 2019-07-05 2022-03-11 산동 단홍 파머수티컬 컴퍼니., 리미티드. SGLTs 억제제의 결정형 및 그 응용
KR102471055B1 (ko) * 2019-07-26 2022-11-28 메드샤인 디스커버리 아이엔씨. Sglt2/dpp4 억제제 및 이의 용도
WO2022063305A1 (zh) * 2020-09-27 2022-03-31 南京明德新药研发有限公司 葡糖苷类化合物的晶型及其应用
WO2022160737A1 (zh) * 2021-01-26 2022-08-04 东宝紫星(杭州)生物医药有限公司 四氢吡喃环类化合物的晶型及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法
CN101503399B (zh) * 2008-02-04 2012-06-27 白鹭医药技术(上海)有限公司 C-芳基葡萄糖苷sglt2抑制剂
CN102146066A (zh) * 2010-02-05 2011-08-10 天津药物研究院 一类含饱和六元环的c-葡萄糖苷衍生物、其制备方法和用途
CN102453026A (zh) * 2010-10-27 2012-05-16 上海艾力斯医药科技有限公司 C-芳基葡糖苷衍生物、制备方法及其应用
TWI631963B (zh) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
CN103772449B (zh) * 2012-10-26 2017-12-26 上海阳帆医药科技有限公司 C‑芳基葡萄糖苷衍生物及其制备方法与用途
US9340521B2 (en) * 2013-03-18 2016-05-17 Green Cross Corporation Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives
CN104109154A (zh) * 2013-04-17 2014-10-22 上海阳帆医药科技有限公司 C-芳基葡萄糖苷衍生物及其制备方法和应用
CN105518014B (zh) 2013-09-09 2018-03-23 上海研健新药研发有限公司 C‑芳基葡糖苷衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
KR20200106156A (ko) 2020-09-11
WO2019134667A1 (zh) 2019-07-11
ES2941108T3 (es) 2023-05-16
JP6917527B2 (ja) 2021-08-11
EP3712147A1 (en) 2020-09-23
EP3712147B1 (en) 2023-01-25
FI3712147T3 (fi) 2023-04-04
CN111372930A (zh) 2020-07-03
JP2021506948A (ja) 2021-02-22
AU2019205072A1 (en) 2020-07-23
CN111372930B (zh) 2021-08-10
US20200331950A1 (en) 2020-10-22
KR102283677B1 (ko) 2021-07-29
EP3712147B8 (en) 2023-04-26
AU2019205072B2 (en) 2021-03-04
US10822365B1 (en) 2020-11-03
EP3712147A4 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
IL282487A (en) TYK2 inhibitors and their use
IL271999A (en) TYK2 inhibitors and uses thereof
IL276095A (en) gcn2 inhibitors and their uses
IL276147A (en) GCN2 inhibitors and uses thereof
EP3587419A4 (en) FGFR INHIBITOR AND APPLICATION OF IT
EP3281942A4 (en) B-lactamase inhibitor and application thereof
EP4076448A4 (en) FLUOROALKYLATED OXADIAZOLES AND THEIR USES
IL276489A (en) ATR inhibitor and its application
IL282090A (en) tyk2 inhibitors and uses thereof
EP3572400C0 (en) EZH2 INHIBITOR AND ITS USE
PT3712147T (pt) Inibidor de sglts e sua aplicação
IL283409A (en) tyk2 inhibitors and uses thereof
IL277794A (en) ATF6 inhibitors and uses thereof
PL3621694T3 (pl) Inhibitory lrrc33 i ich zastosowanie
IL282350A (en) Bernani-RGMC inhibitors and their use
ZA202105752B (en) Haloallylamine compounds and application thereof
IL281798A (en) Prevents FGFR4 and its use
IL279276A (en) ERK inhibitor and use thereof
EP3585809A4 (en) THIOLISOMERASE INHIBITORS AND USES THEREOF
EP3563851A4 (en) ANTITUARY AGENTS AND BROMODOMAIN INHIBITOR
EP3463371A4 (en) KU INHIBITORS AND THEIR USE
IL283106A (en) erk inhibitors and their uses
GB201906914D0 (en) Substituted naphtahlene diimdes and their use
EP3892619A4 (en) SELECTIVE PI3KO INHIBITOR AND USE THEREOF
GB201908884D0 (en) Inhibitors and use